Introductory remarks: Diabetes care in America - "A sense of urgency"

Endocrine Practice

Volumn 12, Issue SUPPL. 1, 2006, Pages 13-15

  Davidson, Jaime A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN;

CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DATA ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; EARLY INTERVENTION; EPIDEMIC; GLYCEMIC CONTROL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INCIDENCE; PATIENT CARE; PATIENT EDUCATION; SELF CARE; UNITED STATES; ARTICLE; ECONOMICS; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; INSULIN RESISTANCE;

BLOOD GLUCOSE; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEALTH CARE COSTS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN RESISTANCE; UNITED STATES;

EID: 33646581702     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.12.s1.13     Document Type: Conference Paper

References (14)

1. Centers for Disease Control and Prevention. Diabetes Fact Sheet. Available at: http://www.cdc.gov/diabetes/pubs/factsheet.htm. Accessed for verification August 18, 2005.
2. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17-20.
3. Grant RW, Buse JB, Meigs JB (University HealthSystem Consortium [UHC] Diabetes Benchmarking Project Team). Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337-442.
4. Menzin J, Langley-Hawthorne C, Friedman M, Boulanger L, Cavanaugh R. Potential short-term economic benefits of improved glycemic control: a managed care perspective. Diabetes Care. 2001;24:51-55.
5. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation. 2000;102:3137-3147.
6. Centers for Disease Control and Prevention. National Vital Statistics Reports. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr53/ nvsr53_05.pdf Accessed for verification August 18, 2005.
7. IMS Physician Survey. Fairfield, CT: IMS Health, Inc., August 2001.
8. Nathan DM. Clinical practice: initial management of glycemia in type 2 diabetes mellitus. N Engl J Med. 2002; 347:1342-1349.
9. Consensus Statement Writing Committee. American College of Endocrinology consensus statement on guidelines for glycemic control. Endocr Pract. 2002;8(Suppl 1):5-11.
10. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [erratum in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
12. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-412.
13. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
14. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care. 1997;20:1847-1853.